DFTX Q4 2022 Earnings — Definium Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DFTXDefinium Therapeutics, Inc.

$2B

Q4 2022 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$14M

Net Income

-$5M

EPS (Diluted)

$0.11

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$170M

Total Liabilities

$19M

Stockholders' Equity

$151M

Cash & Equivalents

$142M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$14M	-$18M	+20.8%
Net Income	-$5M	-$17M	+70.9%